|
Orthologous residues
|
|
GluR1 (human): S849‑p, GluR1 (mouse): S849‑p, GluR1 (rat): S849‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling, mutation of modification site, phospho-antibody, phosphopeptide mapping
|
|
Relevant cell lines - cell types - tissues:
'brain, hippocampus', 293 (epithelial), QT-6 (fibroblast) [CaMK2-alpha (human)], QT-6 (fibroblast) [GluR1 (rat)]
|
|
Cellular systems studied:
cell lines, primary cells
|
|
Species studied:
human, quail, rat
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
CaMK2-alpha (rat)
|
pharmacological inhibitor of upstream enzyme, transfection of constitutively active enzyme, pharmacological activator of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
phorbol ester
|
|
|
|
increase
|
|
|
KN-62
|
|
|
|
decrease
|
|
|
A23187
|
|
|
|
increase
|
|
|
KN-62
|
A23187
|
|
|
inhibit treatment-induced increase
|
|
|